The Non-Coding Oncogene: A Case of Missing DNA Evidence? by Puja Shahrouki & Erik Larsson
MINI REVIEW ARTICLE
published: 12 September 2012
doi: 10.3389/fgene.2012.00170
The non-coding oncogene: a case of missing DNA
evidence?
Puja Shahrouki and Erik Larsson*
Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Edited by:
Peng Jin, Emory University School of
Medicine, USA
Reviewed by:
Francesca Fanini, Istituto Scientifico
Romagnolo per lo Studio e la Cura dei
Tumori, Italy
Ivan Vannini, Istituto Scientifico
Romagnolo per lo Studio e la Cura dei
Tumori, Italy
*Correspondence:
Erik Larsson, Department of Medical
Biochemistry and Cell Biology,
Institute of Biomedicine, University of
Gothenburg, Medicinaregatan 9A,
SE-405 30 Gothenburg, Sweden.
e-mail: erik.larsson@gu.se
The evidence that links classical protein-coding proto-oncogenes and tumor suppressors,
such as MYC, RAS, P53, and RB, to carcinogenesis is indisputable. Multiple lines of proof
show how random somatic genomic alteration of such genes (e.g., mutation, deletion,
or amplification), followed by selection and clonal expansion, forms the main molecular
basis of tumor development. Many important cancer genes were discovered using low-
throughput approaches in the pre-genomic era, and this knowledge is today solidified and
expanded upon by modern genome-scale methodologies. In several recent studies, non-
coding RNAs (ncRNAs), such as microRNAs and long ncRNAs (lncRNAs), have been shown
to contribute to tumor development. However, in comparison with coding cancer genes,
the genomic (DNA-level) evidence is sparse for ncRNAs. The coding proto-oncogenes and
tumor suppressors that we know of today are major molecular hubs in both normal and
malignant cells. The search for ncRNAs with tumor driver or suppressor roles therefore
holds the additional promise of pinpointing important, biologically active, ncRNAs in a vast
and largely uncharacterized non-coding transcriptome. Here, we assess the available DNA-
level data that links non-coding genes to tumor development.We further consider historical,
methodological, and biological aspects, and discuss future prospects of ncRNAs in cancer.
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INTRODUCTION
Already in the late nineteenth century, more than a decade before
the term “gene” was coined, it was suggested that somatic chro-
mosomal alterations could form the basis of tumorigenesis (Von
Hansemann, 1890). Proof had to wait until after the birth of
modern cytogenetics, when the first reported recurrent genomic
aberration in cancer, the famous t(9;22) Philadelphia chromosome
translocation, was described in the 1960s (Nowell and Hungerford,
1961). With more than half a century’s worth of research since that
milestone, great advances into understanding the complex genetic
nature of cancer have been made (Hanahan and Weinberg, 2011).
It is now firmly established that tumor development depends on
genomic instability, acquired genetic variability, and microevolu-
tionary selection (Nowell, 1976). From the discovery of the first
somatic mutation of a proto-oncogene in 1982 (Reddy et al., 1982;
Tabin et al., 1982) to today, hundreds of genes that are somatically
mutated or otherwise genomically altered (amplification, deletion,
translocation,or epigenetic modification) have been identified and
classified as cancer genes (Futreal et al., 2004). Historically, the
main focus has been on coding genes and their protein products,
and only recently have non-coding RNAs (ncRNAs) started to gain
attention as contributors to the development of cancer.
The classic perception of the genome as mainly a substrate
for transcription of protein-coding genes has been significantly
revised during recent years. High-throughput RNA profiling has
revealed that the genome is pervasively transcribed, and that the
number of non-coding genes rivals that of coding genes (Figure 1;
Kapranov et al., 2002; Harrow et al., 2006; Birney et al., 2007). The
discovery of microRNAs has greatly increased the appreciation
for ncRNA beyond classical RNA genes, such as ribosomal and
transfer RNAs. In addition to small ncRNAs such as microRNAs,
transcriptomic studies have revealed an abundance of long ncR-
NAs (lncRNAs) that lie interspersed with coding genes in complex
ways (Carninci et al., 2005; Katayama et al., 2005; Guttman et al.,
2010). These constitute a substantial fraction of all human genes
(Figure 1), and greatly complicate our view of the mammalian
transcriptome.
As awareness grows that ncRNAs participate in important cellu-
lar processes, it is also natural to ask whether alterations in ncRNA
activities contribute to tumor development. Cancer is a disease
of the genome, and ncRNAs should in principle be susceptible
to activation, deactivation, and functional modification through
introduction of the same types of somatic genomic aberrations
that are known to affect coding cancer genes. The completion of
the HUGO project (International Human Genome Sequencing
Consortium, 2004), and the advent of high-throughput meth-
ods for molecular profiling (e.g., microarrays and next-generation
sequencing instruments), has greatly facilitated the study of ncR-
NAs in cancer. However, despite well over 2000 articles relating
to microRNAs in cancer being published in 2011 alone (source:
PubMed), evidence of specific somatic alteration at the level of
DNA still remains relatively sparse. It is also worth noting that
many of the techniques used in the pre-genomic era for find-
ing oncogenes and tumor suppressors, such as cell transforma-
tion using tumor DNA fragments followed by molecular cloning,
or the study of transforming retroviruses (Weinberg, 1982;
www.frontiersin.org September 2012 | Volume 3 | Article 170 | 1









FIGURE 1 | Relative abundances of major human gene categories. The
figure is based on the GENCODE (Harrow et al., 2006) annotation (version
11), and numbers refer to gene counts rather than transcripts. Note that
additional transcribed loci have been described in other high-throughput
gene annotation efforts. Coding genes and lncRNAs were defined as
described previously (Jeggari et al., 2012). Pseudogenes here refer to the
GENCODE “pseudogene” and “polymorphic pseudogene” categories, and
do not include ncRNA pseudogenes. “Misc. RNA” mainly comprises Y
RNAs and 7SK RNAs.
Knudson, 1993), are not inherently limited to coding genes. In
other words, non-coding oncogenes and tumor suppressors, if as
central to cancer as for example MYC and RAS, could in principle
have been discovered several decades ago.
Although the lack of non-coding genes in these early screens
implies that ncRNAs are not as pivotal to tumorigenesis as their
coding counterparts, it would be unwise to rule out crucial con-
tributions based solely on this. Part of the explanation may be
methodological: e.g., the number of oncogenic retroviruses is
limited, and several factors may influence the appearance of cel-
lular genes in viral genomes (Weinberg, 1982). Large-scale cancer
genomics studies to date often have inherent biases toward coding
genes, with e.g., resequencing efforts being directed at the coding
exome. In addition, the concerted action of several dysregulated
ncRNAs may together be important, even if the individual ncRNAs
are incapable of cell transformation. Many of the studies that link
ncRNAs to carcinogenesis are correlational in terms of clinical evi-
dence, but they are often backed up by convincing data from cell
culture and animal model systems. Finally, evidence of recurrent
somatic genomic alteration of ncRNAs may be sparse compared
to coding cancer genes, but it is not completely lacking. In this
review, we assess available DNA-level data for ncRNAs in cancer
(Table 1), and consider how the non-coding sequences that were
once considered as “junk DNA” could prove to be integral players
in cancer through alterations at the genomic level.
SOMATIC GENOMIC ALTERATION OF MICRORNAs IN
CANCER
MicroRNAs are small, ∼22 nucleotides long, regulatory ncRNAs
that modulate gene expression by inhibitory interactions with
mRNAs. They are important for a range of biological processes
(Bartel, 2009), including proper development of the mammalian
embryo (Bernstein et al., 2003). MicroRNAs have been the subject
of intense study during the past decade, and are now show-
ing promise as therapeutic targets and biomarkers in cancer
and beyond (Rosenfeld et al., 2008; Saunders and Lim, 2009).
Numerous studies have revealed frequent differential expression
of microRNAs in tumors compared to normal tissues, or between
clinical subtypes (Lu et al., 2005; Volinia et al., 2006). Although
the overall extent to which these expression changes contribute to
tumorigenesis is not clear, convincing experimental and clinical
data linking dysregulation of specific microRNAs to tumorigene-
sis is available in several cases (recently reviewed in Lujambio and
Lowe, 2012).
Likewise, genomic copy-number alterations (CNAs) in human
cancers have in some cases been linked to microRNA genes, but
separating non-functional passenger events from causal changes
remains a challenge. One often-cited early example, based on
comparative genomic hybridization array data from 227 tumors
(breast, ovarian, and melanoma), showed that a high proportion
of human microRNAs are located in regions of frequent CNA
in cancer (Zhang et al., 2006). However, while this may partially
explain why microRNAs are often deregulated in cancer, it does not
necessarily implicate microRNAs in tumorigenesis. MicroRNAs
are widespread across the genome and large CNAs are frequent
in these tumors, and many of the alterations are therefore likely
not specifically related to microRNAs. This can be exemplified by
the mir-15a/mir-16-1 cluster, encoded by the DLEU2 lncRNA on
chromosome 13q14, which in this study was found to be deleted
in nearly 25% of both ovarian and breast cancer tumors. How-
ever, the 13q14 region harbors numerous other genes, including
the RB1 tumor suppressor, which is inactivated in many can-
cers including ovarian carcinoma (Cancer Genome Atlas Research
Network, 2011). The contribution of mir-15a/mir-16-1 is there-
fore not immediately obvious, and focality/size of aberrations,
and/or additional functional data, needs to be taken into account
to reliably pinpoint causal ncRNA genes.
In the case of mir-15a/mir-16-1, convincing data in support of a
tumor suppressor role comes from chronic lymphocytic leukemia
(CLL). In one of the pioneering studies that was able to link
somatic alteration of microRNAs to cancer, it was shown that
the 13q14 deletion, although already known to be frequent in
CLL, was often restricted to a smaller 30 kb region encompassing
these microRNAs (Calin et al., 2002). Later studies showed that
mir-15a/mir-16-1 are proapoptotic (Cimmino et al., 2005) and,
importantly, that deletion of these microRNAs in mice leads to CLL
predisposition (Klein et al., 2010). However, in ovarian cancer it
should be noted thatRB1, but not the nearbyDLEU2/mir-15a/mir-
16-1, shows a clear pattern of focal deletion (Cancer Genome Atlas
Research Network, 2011), suggesting that reported mir-15a/mir-
16-1 deletions in ovarian cancer (Zhang et al., 2006) could be
passenger events. This example illustrates the difficulties involved
in associating genomic aberrations with causal genes, even in the
presence of convincing experimental data from other cancer types.
Some of the earliest evidence that microRNAs can have onco-
genic properties come from studies of the mir-17-92 cluster on
chromosome 13q31, a region known to be amplified in several can-
cers including diffuse large B-cell lymphoma (DLBCL; Rao et al.,
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Table 1 | NcRNAs specifically targeted by somatic genomic alterations in cancer.
Name Class Locus Somatic
alteration
Function Cancer type Reference
mir-15a/mir-16-1 microRNA cluster 13q14 Deletion Tumor suppressive CLL Calin et al. (2002)
mir-17-92 microRNA cluster 13q31 Amplification Oncogenic Lymphoma Ota et al. (2004)
LOC285194 and BC040587 lncRNA 3q13 Deletion Tumor suppressive Osteosarcoma Pasic et al. (2010)
NC25 lncRNA 6q13 Mutation Tumor suppressive Endometrial Perez et al. (2008)
GAS5 lncRNA/snoRNA 11q25 Gene fusion Unknown B-cell lymphoma Nakamura et al. (2008)
PTENP1 Pseudogene/lncRNA 9p13 Deletion Tumor suppressive Colon Poliseno et al. (2010)
SNORA42 snoRNA 1q22 Amplification Oncogenic Lung Mei et al. (2012)
U50 snoRNA 6q14 Mutation Tumor suppressive Prostate, breast Dong et al. (2008, 2009)
1998). Although 13q31 also contains other genes, the mir-17-92
precursor was shown to be the only one at the focal center where
expression correlated with copy-number amplitude in DLBCL
(Ota et al., 2004). Based on a mouse model of B-cell lymphoma,
it was later shown that forced expression of mir-17-92 accelerates
tumor development through cooperation with c-Myc (He et al.,
2005). MiR-19 was eventually pinpointed as the main oncogenic
microRNA derived from this cluster, together with associated key
targets in the phosphatidylinositol-3-OH kinase pathway (Olive
et al., 2009; Mavrakis et al., 2010). Similarly, miR-155 causes B-
cell malignancy when overexpressed in mouse B-cells (Costinean
et al., 2006) while also frequently being highly expressed in human
lymphomas (Eis et al., 2005), although it is unclear whether this
primarily happens through transcriptional activation or genomic
amplification.
Several other studies have linked CNA in cancer to microRNA
genes, albeit at different levels of confidence in terms of functional
significance. In one case, 16 microRNA genes were found to show
correlations between expression level and copy-number ampli-
tude in different regions frequently exposed to CNA in multiple
myeloma (Lionetti et al., 2009). Frequent amplification of mir-30d,
mir-151, and the C19MC microRNA cluster has been observed in
hepatocellular carcinoma (Liu et al., 2011; Augello et al., 2012).
Likewise, frequent copy-number gains, which correlate with gene
expression, have been observed for mir-30b in oral squamous cell
carcinomas (Shao et al., 2012). However, mir-30b is proximal to
MYC, a target of amplification in numerous cancers, and the value
of this category of observations is therefore unclear in the absence
of data on focality or additional functional investigations.
In addition to CNA, microRNAs should in principle be sus-
ceptible to inactivation through somatic mutations, although the
evidence of this has been relatively sparse so far. In one study,
15 cancer-implicated microRNAs were screened for mutations in
91 tumor cell lines, but no changes within mature microRNA
sequences were identified (Diederichs and Haber, 2006). Likewise,
mutation screening of 712 microRNAs in 86 ovarian tumors iden-
tified only five mutations, of which all were in different genes and
only one in the mature sequence (Ryland et al., 2012). Sequencing
of microRNAs that are dysregulated in CLL identified a mixture
of rare (1–3 out of 75 patients) somatic and germline mutations
in 8/42 microRNAs tested, including a germline substitution in
mir-16-1 in two patients, while only a few sequence abnormali-
ties were found in 160 healthy controls (Calin et al., 2005). While
the idea that microRNA mutations may be a predisposing factor
in familial CLL is intriguing, more detailed genetic studies on
affected families are required to better establish this. Another
study based on 255 CLL patients found rare somatic mutations
in the stem region of miR-16 in two cases (Ouillette et al., 2011). A
somatic substitution was found in mir-518d in the central region
of the stem, based on whole-genome resequencing of a single case
of melanoma, but at the same time 33,344 other somatic base
substitutions were identified (Pleasance et al., 2010). More com-
prehensive studies are needed to safely determine whether such
rare mutations are functional and under selection during tumor
evolution.
Non-coding RNA-associated proteins, such as those required
for microRNA function and biogenesis, are also of interest in
this context, and several studies show that these can be targets of
somatic alteration in cancer. For example, in microsatellite insta-
ble gastric and colorectal cancers, recurrent frame-shift mutations
were found in AGO2 and TNRC6A (Kim et al., 2010). Likewise,
recurrent somatic mutations (among other, a missense mutation)
were identified in the RNase IIb domain ofDICER1, in 30/102 non-
epithelial ovarian tumors (Heravi-Moussavi et al., 2012). Although
these mutations are not targeted at specific microRNAs, they pro-
vide strong support for the idea that altered ncRNA function is
important for tumorigenesis.
GENOMIC ALTERATION OF lncRNAs: A LONG STORY MADE
SHORT
Long non-coding RNAs are broadly defined as long (arbitrarily
>200 nt) transcripts that lack protein-coding capacity but oth-
erwise often have mRNA-like properties, including multi-exonic
gene structures and poly(A) tails. Studies point to diverse molec-
ular roles, including recruitment of histone-modifying complexes
to chromatin (e.g., XIST, HOTAIR; Plath et al., 2003; Rinn et al.,
2007) and regulation of transcription and splicing through inter-
actions with relevant factors (Bernard et al., 2010; Kino et al.,
2010). Although early examples were described more than 20 years
ago, more recent studies have revealed that mammalian genomes
encode thousands of lncRNAs that are often developmentally reg-
ulated, and show weak but significant patterns of evolutionarily
conservation (Ponjavic et al., 2007; Guttman et al., 2009). Their
biological importance has been debated, but novel lncRNAs are
now being characterized at increasing frequency, and these have
been shown to have essential roles, e.g., in vertebrate development
(Ulitsky et al., 2011), pluripotency (Guttman et al., 2011), and
genome stability (Huarte et al., 2010).
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Several studies hint at important roles in oncogenesis for lncR-
NAs. For example, HOTAIR expression is high in breast cancer
tumors that are predisposed to metastasize, and its inhibition
blocks metastasis in mouse models (Gupta et al., 2010), and
MALAT1 expression correlates with metastases and survival in
lung cancer (Ji et al., 2003). Numerous other lncRNAs are altered
in cancer at the level of gene expression (recently reviewed in
Prensner and Chinnaiyan, 2011), but our knowledge is still lim-
ited when it comes to targeted genomic alterations. One recent
investigation showed that two lncRNA genes on chromosome
3q13.31, LOC285194 and BC040587, were frequently deleted in
osteosarcoma (Pasic et al., 2010). Notably, the deletions were often
highly focal, but sometimes also included the nearby protein-
coding tumor suppressor LSAMP. The results suggest that the
genes in this region, which are also coexpressed, may function
as a unit. Furthermore, deletion of either lncRNA was associ-
ated with poor survival (Pasic et al., 2010). Focal deletion has
also been observed in the case of a PTEN pseudogene, PTENP1,
in colon cancer, which can regulate its tumor suppressive cod-
ing counterpart by competitive binding to common microRNAs
(Poliseno et al., 2010). This intriguing mechanism has been fur-
ther explored in cancer (Sumazin et al., 2011), and is supported by
the observation that microRNAs with many targets tend to have a
diluted effect on each individual target (Arvey et al., 2010). Further
computational studies are needed to determine whether interac-
tions between microRNAs and other ncRNAs are widespread and
conserved (Jeggari et al., 2012).
A few studies suggest that somatic mutations in lncRNAs may
be important in cancer, but this remains poorly explored. In one
case, a set of 15 highly expressed and conserved lncRNAs were
screened for mutations in both cancer cell lines and unmatched
normal controls (Perez et al., 2008). Three lncRNAs showed con-
sistent alterations at specific nucleotide positions in at least two
cancer cell lines, although it could not be excluded that these
represented rare polymorphisms. The mutations were not recapit-
ulated in a panel of 48 matched endometrial tumors and normals,
but another lncRNA, NC25, here displayed a striking pattern of
somatic alteration, with mutations being present in almost half
(23/48) of the patients at one of four distinct positions (Perez
et al., 2008). Mutations have also been described in the 3′-end of
MALAT1 (Xu et al., 2011), a lncRNA known to be highly expressed
in metastases originating from different cancers (Ji et al., 2003;Ying
et al., 2012). It was also determined that the 3′-end of MALAT1
confers the main biological activity, but the putative functional
impact of the actual mutations was never evaluated (Xu et al.,
2011).
Ultraconserved regions (UCRs) are genomic elements of
near-perfect evolutionary conservation in multiple mammalian
genomes, some of which overlap with transcribed regions (exonic,
partly exonic, or intronic; Bejerano et al., 2004; Sandelin et al.,
2004). UCRs are often located in cancer-associated genomic
regions, and several UCRs are transcribed into non-coding tran-
scripts (T-UCRs) whose expression is altered in cancer and
is correlated with clinical subtypes and cancer-relevant cellular
processes (Calin et al., 2007; Mestdagh et al., 2010). Both somatic
and germline mutations have been identified in T-UCRs in col-
orectal cancer and CLL (Wojcik et al., 2010), but further study
is needed to firmly establish if T-UCRs are specific targets of
mutation in cancer, or confer heritable risk.
Long non-coding RNA have also been reported to participate
in somatic gene fusions. The GAS5 lncRNA gene, which also har-
bors several intronic small nucleolar RNAs (snoRNAs), has been
found to fuse with the BCL6 proto-oncogene in a patient with
B-cell lymphoma (Nakamura et al., 2008). Similarly, an ETV1
translocation to an androgen-regulated lncRNA, PCAT-14, has
been reported in prostate cancer (Prensner and Chinnaiyan, 2011;
Prensner et al., 2011). Most likely, lncRNA genes in these cases only
contribute regulatory DNA to drive aberrant protein expression,
and whether oncogenic lncRNAs themselves can be activated or
functionally modulated through genomic translocation remains
to be determined.
SnoRNAs IN TUMORIGENESIS
Small nucleolar RNAs constitute a well-characterized class of
structural RNAs of 60–300 nucleotides in length, with roles in
chemical modification of ribosomal RNAs. Emerging evidence
suggests that snoRNAs may have specific roles in oncogenesis
(reviewed in Williams and Farzaneh, 2012). As an example, tumor-
enriched snoRNAs have been identified in lung cancer, and these
are detectable in blood plasma at elevated levels in patients com-
pared with healthy controls (Liao et al., 2010). Recent work also
suggests that snoRNAs may be specific targets of somatic genomic
alteration. In a study based on 10 lung cancer cell lines, it was
shown that SNORA42, but not its protein-coding host gene,
exhibits a high degree of correlation between RNA level and
genomic copy-number (Mei et al., 2012). Together with func-
tional data from loss- and gain-of-function experiments in cell
lines and mouse xenograft models, this implicates an oncogenic
role for SNORA42. However, it should also be noted that several
other genes in the same genomic region (1q22) display a similar
relationship between copy-number and RNA level (Li et al., 2006).
In addition to SNORA42, the snoRNAU50 has been impli-
cated in prostate and breast cancer, where it is commonly deleted
together with other genes in the 6q14-22 region (Dong et al., 2008,
2009). Interestingly, identical 2-bp somatic deletions in U50 were
discovered in 9/89 of prostate and 4/49 breast tumors studied, and
germline homozygosity for the same deletion was associated with
prostate cancer in a larger case-control study (Dong et al., 2008,
2009). Collectively, these studies are intriguing and point to spe-
cific roles for snoRNAs in cancer, beyond housekeeping functions
related to protein synthesis.
CONCLUDING REMARKS AND PERSPECTIVES
Here, we have attempted to summarize current evidence for spe-
cific somatic alteration of ncRNAs in cancer (Table 1). Though
only briefly discussed here, germ line mutations are also of para-
mount importance: in addition to potential benefits for early can-
cer diagnostics, associations between natural genetic variants, or
familial mutations, and cancer susceptibility can pinpoint impor-
tant cancer ncRNAs. In addition, only when considering both
genetic and epigenetic aspects will the picture be complete.
It is already clear that altered ncRNA function, by genomic
change or other means, is of importance in tumorigenesis. How-
ever, due to the rapid evolution of high-throughput genomics, the
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detailed map of ncRNA alterations in cancer is likely to change sig-
nificantly in the near future. In particular, resequencing in cancer
is transitioning from whole-exome to whole-genome (Meyerson
et al., 2010), effectively putting more emphasis on non-coding
sequences. This technique is not without challenges, including the
separation of low-frequency functional alterations from numer-
ous non-contributing ones (Boehm and Hahn, 2011). However,
increasingly comprehensive patient cohorts will eventually help
reveal whether specific somatic alteration of ncRNAs is com-
monplace in cancer. In addition to improving our understanding
of tumor development, these studies hold the exciting promise
of pinpointing important novel ncRNAs that are crucial to the
physiology of the normal mammalian cell.
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